Hematology/Oncology

Top Story

Standard neoadjuvant chemoradiotherapy underused for advanced rectal cancer

May 25, 2016

Read the Perspective from Joshua Shaeffer Hill, MD, MS

Although the use of standard-of-care neoadjuvant chemoradiotherapy has increased among patients with advanced rectal cancers, only half of eligible patients receive this treatment, according to an analysis of data from the National Cancer Data Base.

Socioeconomic factors may play a role in those rates, the researchers wrote in the study.

In the Journals

Prasugrel fails to ease vaso-occlusion burden in sickle cell disease

May 24, 2016
Treatment with prasugrel did not significantly reduce the rate of vaso-occlusive crisis in children and adolescents with sickle cell anemia, according to the results of…
Meeting News CoveragePerspective

Granisetron patch prevents CINV for patients with hematologic malignancies

May 24, 2016
Granisetron transdermal system patch prevented chemotherapy-induced nausea…
In the Journals

Overweight patients less likely to die of colorectal cancer

May 24, 2016
BMI at the time of colorectal cancer diagnosis is associated with mortality risk, according to results of a retrospective observational study.Patients categorized as…
In the Journals

Geriatric events increase morbidity, costs among older patients who undergo cancer surgery

May 24, 2016
Older individuals who underwent cancer surgery appeared likely to experience geriatric events, such as falls and fractures, delirium and dehydration.These events —…
More News Headlines »
CME

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by educational grants from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty-five percent of lung cancers are non-small…
More »
Video
Meeting News Coverage

VIDEO: Some women with early-stage breast cancer can safely avoid adjuvant chemotherapy

May 4, 2016
More »
Featured
AACR Annual Meeting

AACR Annual Meeting

CME Video

NSCLC Treatment on Target: Examining New Evidence and Advances

This activity is supported by an educational grant from Genentech, Inc. and Merck & Co., Inc.

Globally, lung cancer is the leading cause of cancer-related deaths. Eighty five percent of lung cancers are non-small…
More »
Current Issues
View the Current Issue
HemOnc Today
morganatic-roan
morganatic-roan